SCHEMBL3558749

SCHEMBL3558749

COc1cc2cc([C]=O)[nH]c2c(OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
LMNA P02545 1/20 0.56
CYP19A1 P11511 2/20 0.43
NQO2 P16083 2/20 0.43
MAOA P21397 2/20 0.38
HSD17B10 Q99714 2/20 0.37
CA9 Q16790 2/20 0.37
NPC1 O15118 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA7 P43166 1/20 0.37
CA13 Q8N1Q1 1/20 0.37
GRIN2D O15399 2/20 0.36
GRIN3B O60391 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2A Q12879 2/20 0.36
GRIN2B Q13224 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13344922 0.75 KDM4E (0.58) KDM4EALDH1A1HPGDLMNACYP19A1
SCHEMBL3558751 0.75 ALDH1A1 (0.58) KDM4EALDH1A1HPGDLMNACYP19A1
SCHEMBL14234928 0.74 KDM4E (0.57) KDM4EALDH1A1HPGDLMNACYP19A1
SCHEMBL27518825 0.74 KDM4E (0.57) KDM4EALDH1A1HPGDLMNACYP19A1
SCHEMBL1771123 0.72 HPGD (1.00) KDM4EALDH1A1HPGDLMNACYP19A1
SCHEMBL12596874 0.72 KDM4E (0.77) KDM4EALDH1A1HPGDLMNACYP19A1
Hydrochloric Acid SCHEMBL3555727 0.71 HPGD (0.97) KDM4EALDH1A1HPGDLMNACYP19A1
SCHEMBL2908238 0.71 KDM4E (0.75) KDM4EALDH1A1HPGDLMNACYP19A1
SCHEMBL28941241 0.71 KDM4E (0.75) KDM4EALDH1A1HPGDLMNACYP19A1
SCHEMBL3555723 0.71 HPGD (0.75) KDM4EALDH1A1HPGDLMNACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
EP-1809603-A4 NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LTD (NZ) 2009-09-02 EP disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed
EP-1809603-A1 NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY Auckland Uniservices Limited (NZ) 2007-07-25 EP disclosed
WO-2006043839-A1 NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A KDM4E 856/4885ALDH1A1 77/4885HPGD 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.